News

Reportedly, in 2006, Health Discovery has sued Ciphergen Biosystems in Federal District Court for infringement of several of its patents covering the use of support vector machines (SVMs)

Rik Deitsch, chairman and CEO of Nutra Pharma, said: “We were extremely pleased with our fourth quarter Cobroxin sales, especially given its initial limited retail availability. With the

Millipore’s fourth quarter earnings per share were $0.78 per share, compared to $0.56 per share in the fourth quarter of 2008. Non-GAAP earnings per share were $1.00, compared

The company said that the newly patented method extends the ability of the Entelos Metabolism PhysioLab platform to explore, simulate, and predict differences in fuel utilisation between patients,

Henri Termeer, chairman and chief executive officer at Genzyme, said: “Scott Canute is among the very top people in the pharmaceutical manufacturing field. He is widely respected for

The study indicates that in animals treated with PLX cells, there were differences to the control groups in the following parameters: improvement in sensory and motor deficits, reduction

The MermaiHD study met the primary endpoint to show an effect on voluntary motor function. In addition, data from the 437 huntington patients, who participated in the study

The company said that the purchase price is $110m cash subject to a customary working capital adjustment. The acquisition is expected to close in the first quarter of

Dr Nielsen most recently served as executive vice president of pharmaceuticals for URLMutual Pharmaceutical, where he lead new product development and licensing activities for both products and drug